Was the market expecting this ?It was a surprise to me since they've only recent kept the guidance unchanged.Seems like everyone is thinking the same, ashahriar
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%